Pay in 4 interest-free payments of $6.42 Learn more
Ships within 48 hours · Estimated delivery Aug 26 - Aug 31
1 Of the 145,410 patients treated with GLP1 and 291,667 treated with dipeptidyl peptidase 4 (DPP4) inhibitor treatment, 76 and 184, respectively, developed thyroid cancer
S.VeltmanD
Market growth increased biologic therapies across healthcare treatment plans
Key Takeaways Retatrutide targets three hormones (GLP-1, GIP, glucagon), tirzepatide targets two (GLP-1, GIP), and semaglutide targets one (GLP-1) At 68 weeks, retatrutide achieved 28.7% average weight loss, tirzepatide approximately 22%, and semaglutide around 17% on the highest doses Side effects are similar across all three medications, mainly digestive issues like nausea and diarrhoea Retatrutide is not yet approved and won't be available until mid-2026 at the earliest Retatrutide is not yet approved and is not currently available in the UK Tirzepatide (Mounjaro) and semaglutide (Wegovy) are both available now in the UK through NHS or private providers By entering I agree to the Terms and Conditions
Dulaglutide significantly reduced the risk of this primary composite outcome by 12% compared to placebo (p=0.026)
US$ 24.71
US$ 22.59
US$ 24.83
